Format

Send to

Choose Destination
Drugs. 2019 May;79(7):693-703. doi: 10.1007/s40265-019-01103-2.

Are All Dopamine Agonists Essentially the Same?

Author information

1
IRCCS San Raffaele Pisana, Center for Parkinson Disease, Rome, Italy.
2
San Raffaele Cassino, Rome, Italy.
3
Lundbeck, Research and Development Department, Copenhagen, Denmark.
4
Casa di Cura privata Policlinico (CCPP), Milan, Italy.
5
IRCCS San Raffaele Pisana, Center for Parkinson Disease, Rome, Italy. fabrizio.stocchi@sanraffaele.it.
6
San Raffaele University, Rome, Italy. fabrizio.stocchi@sanraffaele.it.

Abstract

Dopamine agonists (DAs) represent an excellent treatment option for patients with Parkinson's disease, in both the early and advanced stages of the disease, improving motor symptoms, lowering the incidence of motor complications, and addressing several non-motor symptoms. Indeed, each of these compounds have different pharmacokinetic and pharmacodynamic properties, resulting in a unique efficacy and safety profile. Comorbidities, prominent non-motor symptoms and individual subjects' clinical characteristics should guide the choice of a specific DA, allowing better management of the patient by optimizing the DA benefit/risk ratio. In this article we discuss brain distribution of dopamine receptors and their role in each of the dopaminergic pathways, the pharmacological profile of non-ergoline DAs and class-related adverse effects, as reported from post-marketing studies.

PMID:
30968290
DOI:
10.1007/s40265-019-01103-2

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center